Case report: Invasive aspergillosis successfully treated with voriconazole without recurrence during subsequent bone marrow transplantation.
Invasive aspergillosis is an important cause of morbidity and mortality among immunosuppressed oncology patients. We report a 17-year-old patient with a T cell acute lymphocytic leukemia and invasive aspergillosis treated with voriconazole who remained infection-free during bone marrow transplant.
Chow
Emilie
E
Mattel Children's Hospital at University of California, Los Angeles, USA.
Moore
Theodore
T
Nielsen
Karin
K
D000293:Adolescent; D000935:Antifungal Agents / Q000008:administration & dosage*; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D016026:Bone Marrow Transplantation; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D016469:Fungemia / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D007262:Infusions, Intravenous; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D011743:Pyrimidines / Q000008:administration & dosage*; D018570:Risk Assessment; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole